Evaluation 2 of "Pharmaceutical Pricing and R&D as a Global Public Good"

Evaluator 2

No 2025-30, The Unjournal Evaluations from The Unjournal

Abstract: Strengths and achievements:1. Applies a classic public-good model to explain why U.S. drug prices exceed those in ROW and remain below the global optimum2. Empirical markups dispel the notion that non-U.S. markets fully free-ridePositive GDP"price correlation aligns with theoretical predictionsCritiques, limitations, and suggestions:1. Empirical tests are correlational and could have alternate explanations2. Theoretical results rest on the assumption of optimal centralized government action3.

Date: 2025-06-15
References: View references in EconPapers View complete reference list from CitEc
Citations:

Published in The Unjournal

Downloads: (external link)
https://unjournal.pubpub.org/pub/e2pharmpricing (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:bjn:evalua:e2pharmpricing

DOI: 10.21428/d28e8e57.072621d7/7ae8ab52

Access Statistics for this paper

More papers in The Unjournal Evaluations from The Unjournal
Bibliographic data for series maintained by Davit Jintcharadze ().